{"nctId":"NCT00891462","briefTitle":"Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)","startDateStruct":{"date":"2009-04"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":561,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium bromide"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium bromide"]},{"label":"3","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Aclidinium bromide","otherNames":[]},{"name":"Aclidinium bromide","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 2009; postbronchodilator FEV1/FVC \\< 70%, and postbronchodilator FEV1 â‰¥ 30% and \\< 80% predicted\n* Current or former cigarette smokers\n\nExclusion Criteria:\n\n* Patients who have been hospitalized for an acute COPD exacerbation within 3 months before the first visit\n* Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1\n* Patient with any clinically significant respiratory conditions other than COPD, cardiovascular conditions or mental illness\n* History or presence of asthma verified from medical records\n* Chronic use of oxygen therapy greater than or equal to 15 hours per day\n* Patient with uncontrolled infection due to HIV and/or active hepatitis\n* Patients with a history of hypersensitivity reaction to inhaled anticholinergics\n* Patients with clinically significant cardiovascular conditions, including myocardial infarction during the previous 6 months, newly diagnosed arrhythmia within the previous 3 months, unstable angina, unstable arrhythmia that had required changes in pharmacological therapy or other intervention.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Morning Pre-dose Forced Expiratory Volume in 1 Second (FEV1)","description":"Change from baseline in trough forced expiratory volume in 1 second before the morning dose of aclidinium bromide, Last Observation Carried Forward (LOCF)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.025","spread":"0.015"},{"groupId":"OG001","value":"0.062","spread":"0.015"},{"groupId":"OG002","value":"0.099","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Peak Forced Expiratory Volume in 1 Second (FEV1)","description":"Change From Baseline in Peak FEV1 (L) at Week 12, Last Observation Carried Forward (LOCF)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.071","spread":"0.016"},{"groupId":"OG001","value":"0.217","spread":"0.016"},{"groupId":"OG002","value":"0.263","spread":"0.016"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":186},"commonTop":["Chronic obstructive pulmonary disease"]}}}